RxDoctor Payments Data

Victor Pedroza, MD

Family Medicine · Los Angeles, CANPI 1760527055

Payments from drug & device makers

$2,755in general payments, 2019–2025

Across 114 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$479
  • Amgen$456
  • Sumitomo Pharma America, Inc.$311
  • Novartis$262
  • Pfizer$239
  • Boehringer Ingelheim$201
  • plus $806 from 11 others

What the payments were for

  • Speaking & faculty fees$592%
  • Food & beverage$2,67697%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,755 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$39,737
Medicare patients
96
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$179,668
LinzessLinaclotide188$99,983
JanuviaSitagliptin Phosphate137$95,994
FarxigaDapagliflozin Propanediol105$64,479
JardianceEmpagliflozin77$52,296
EliquisApixaban65$45,209
XareltoRivaroxaban35$26,034
TrulicityDulaglutide29$25,080
MyrbetriqMirabegron53$24,566
TradjentaLinagliptin41$24,063
Combivent RespimatIpratropium/Albuterol Sulfate26$12,804
KerendiaFinerenone14$10,949
EntrestoSacubitril/Valsartan14$10,674
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,435
Lopinavir-RitonavirLopinavir/Ritonavir13$6,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$479$99,983188 claims
MerckJanuvia$14$95,994137 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$201$89,164144 claims
AstraZenecaFarxiga$189$64,479105 claims
PfizerEliquis$239$45,20965 claims
BayerKerendia$196$10,94914 claims
NovartisEntresto$262$10,67414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →